We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
BioCardia Inc | NASDAQ:BCDAW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0003 | -2.31% | 0.0127 | 0.0025 | 0.0175 | 0.013 | 0.0127 | 0.013 | 5,894 | 05:00:08 |
Webcast link: https://www.webcaster4.com/Webcast/Page/2019/36064
In addition, Dr. Altman will be available for virtual one-on-one meetings beginning on September 1, 2020 and through September 4, 2020. To schedule a meeting, please contact Eric Lahiji at eric@ldmicro.com.
About BioCardia
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.
Media Contact:Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274
Investor Contact:David McClung, Chief Financial OfficerInvestors@BioCardia.com(650) 226-0120
1 Year BioCardia Chart |
1 Month BioCardia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions